Depletion of cellular immunity as a consequence of conditioning before allogeneic hematopoietic SCT (HSCT) frequently results in CMV reactivation, which may in turn lead to life-threatening infections and require timely antiviral treatment. We have investigated the functional signatures of CMV-specific CD4 þ and CD8 þ T-cells in 191 samples from 118 individuals. We compared healthy donors with both patients with high and undetectable viral loads, and those who controlled and did not control their CMV reactivations. Polychromatic flowcytometric measurements of CD154 (CD40L), intracellular cytokines (IFNc, IL2) and a degranulation marker (CD107a) allowed us to assess the functional status of various T-cells simultaneously. We found that dual IFNc/ IL2-producing CD8 þ T-cells were present in patients controlling their CMV reactivations but absent from noncontrollers. CD8 þ T-cells that produce only IFNc were the most abundant subtype, but they most likely represent non-protective memory cells. Distinct functional signatures were examined by hierarchical clustering, and this revealed that, unlike polyfunctional CD8 þ T-cells, CD8 þ T-cells that produce IFNc alone were not functioning in concert with other subsets. In conclusion, our study revealed functional signatures that may be useful for immune monitoring, and it could change the interpretation of previous studies that assessed only IFNc.
Introduction
CMV, a virus from the beta-herpes virus family, is a common pathogen that infects 50-90% of the adult population. 1 In immuno-competent individuals, it causes minor symptoms, such as self-limiting fever or tonsillitis. This is a result of the normal functioning of the immune system as a whole, especially of CMV-specific T-cells, which have a key role in CMV control. Evidence for a primary role of CMV-specific T-cells in virus control is provided by the uncontrolled viral replication and endorgan diseases observed in immune-deficient individuals with severely impaired T-cell function, such as patients with primary or secondary immune deficiencies. [1] [2] [3] [4] CMV remains a significant cause of morbidity and mortality in immuno-compromised children after hematopoietic SCT (HSCT), even though the clinical outcome of CMV infection after transplantation has improved because of advances in diagnostic and therapeutic strategies. 5, 6 Despite these advances, the proper reconstitution of CMVspecific immunity is the most important factor in controlling the reactivation of the virus and in establishing longterm protection. 7 Restoration of adaptive immunity after HSCT is a slow process. Naı¨ve T-cells first appear at about 4 months after HSCT, and the full restoration of the naı¨ve T-cell pool may require 1 to 2 years. Although the T-cell counts recover much earlier by peripheral expansion, the patients suffer from frequent infections, demonstrating the inadequate function of the T-cells. 8 Current treatment strategies involve prophylactic or pre-emptive antiviral treatment. However, both of these approaches lead to significant overtreatment. 9, 10 At the same time, late CMV disease is frequently observed in patients who obtain antiviral treatment within the first 3 months after HSCT. 11 Several groups have monitored the recovery of CMVspecific immune responses after HSCT. These studies included CD8 þ tetramer detection in a sizeable cohort (24 patients, 12 87 patients 2 and 116 patients 13 ), multiple smaller-size cohorts that were assessed only for an IFNg production in CD4 þ and CD8 þ T-cells (52 patients 14 ; 30 patients; 15 32 patients 16 and 32 patients 17 ), and one study of CD4 þ T-cell production of IFNg and IL2 (42 patients 18 ). Overall, our understanding of protective factors remains limited. One conclusion of the preceding studies was that neither the number of tetramer-positive cells 19 nor IFNg production are sufficient parameters for monitoring disease. 16 This motivated us to develop a single eight-color panel of antibodies that enabled the detection of four essential functions from one sample in both CD4 þ and CD8 þ T-cells. We chose to monitor the CMV Ag-T-cellspecific production of IFNg and IL2, the upregulation of CD40L (as an early marker of the CD4 þ T-cell response 20 ) and the membrane exposure of CD107a (as a marker of degranulation 21 ). To achieve high sensitivity of our assay with minimal blood-sample size requested from our pediatric patients, we preferred to investigate the whole sample in a single tube, which limited us to eight useful fluorescence markers per cell on our instrument. Thus, other documented T-cell functions, such as secretion of TNFa or MIP-1b, could not be included in the study. As the MIP-1b presence was reported to be a marker of terminal differentiation of T-cells 22, 23 while TNFa is mostly produced by the same cells as IFNg, [22] [23] [24] our ability to detect CMV protection-related functional signatures should not be impaired.
Materials and methods

Patients and healthy donors
Blood samples were obtained from 61 patients (38 boys and 23 girls) who underwent allo-HSCT. On the basis of their history of CMV reactivation they were divided into four groups. The groups were as follows: CMV naı¨ve after HSCT (CMV-NAH), defined as CMV-seronegative patients transplanted using CMV-negative donor graft without any documented CMV reactivation, n ¼ 14. CMV-seropositive without reactivations group (CMV-WR, n ¼ 21) included patients without PCR-documented CMV reactivation despite the donor and/or recipient were CMV-seropositive. CMV-positive controlling reactivations (CMV-CR, n ¼ 16) included patients who experienced PCR-documented CMV reactivations in the past, but there was no viral load detected by PCR at the sampling time or within a follow-up of at least 3 months and no clinical manifestation of CMV disease was reported (and no antiviral therapy was administered). Patients failing these criteria were designated CMV non-controlling (CMV-NC, n ¼ 10). Further patient characteristics are listed in Table 1 . We also examined 19 adult healthy volunteers who gave their informed consent. Leftover blood samples were obtained from 38 children at an outpatient WBC count check-up with their guardians' informed consent. Healthy donor characteristics are listed in Table 2 . Ethical approval for this study was obtained from the University Hospital Motol institutional review board. All patients and volunteers provided informed consent according to the Helsinki Declaration. All patients and volunteers were studied prospectively.
Monitoring of CMV viral load, pre-emptive therapy and schedule of T-cell monitoring Monitoring of CMV viral loads in whole blood was performed using RQ-PCR. The viral loads were normalized to 10 000 human genomic equivalents obtained by quantification of the albumin gene. 25 Normalized viral load above 100 was considered clinically significant and preemptive therapy with ganciclovir was initiated. Patients were treated with i.v. ganciclovir (5 mg/kg/12 h) for 2 weeks. Maintenance dose of i.v. ganciclovir (5 mg/kg/day) or p.o. valganciclovir (900 mg/m 2 /day) for additional 1-2 weeks. Pre-emptive therapy was discontinued after negative PCR result or a clinically significant decrease in viral load, after minimum of 3 weeks of treatment. Foscarnet (i.v. 60 mg/kg/12 h) was added to the therapy schedule or used to replace ganciclovir or valganciclovir after initiation of pre-emptive therapy when the viral load continued to be clinically significant beyond the third week of treatment. PCR monitoring began on day 7 post-HSCT and was performed weekly until 3 months post-HSCT. Afterwards, it was performed every 2 weeks until 6 months post-HSCT and once a month thereafter. In addition, PCR was performed weekly during reactivation, or during continuous high immunosuppressive therapy in cases of GVHD.
Monitoring of CMV-specific T-cells began on day þ 28 and was performed weekly during hospitalization and then again on days þ 56, þ 90, þ 180 and þ 365 post-HSCT. In cases of reactivation, patients were monitored every week until the CMV viral load was negative by PCR results.
Patients one and more years post-HSCT were monitored once a year at the HSCT anniversary.
CMV-specific T-cell assessment Purified PBMCs obtained using Ficoll-Paque (Pharmacia, Uppsala, Sweden) were washed once with PBS and resuspended in 10 mL of complete RPMI 1640 media (RPMI 1640 supplemented with 10% heat-inactivated FCS, 100 U/mL penicillin, 100 mg/mL streptomycin sulfate and 1.7 mM sodium glutamate) and rested overnight at 37 1C. The next morning, PBMCs were adjusted to 20 Â 10 6 cells/mL. Co-stimulatory antibodies (CD28/ CD49d, 1 mg/mL, BD Biosciences, San Jose, CA, USA) and CD107 Alexa488 (clone B-T47, Exbio Praha, Prague, Czech Republic), along with cells aliquoted at 100 mL, were added to each well on a 96-well plate containing 1 mg/mL of each peptide and 10 mg/mL of whole-CMV lysate. Both an unstimulated and a positive control (anti-CD3, 10 mg/mL, Exbio) well were included in each assay. Cells were incubated for 2 h at 37 1C. Afterwards, brefeldin A (10 mg/mL, Sigma-Aldrich, St Louis, MO, USA) was added to each well. Stimulation continued for additional 4 h at 37 1C. Following incubation, 2 mL of 0.1 mM EDTA (SigmaAldrich) and LIVE/DEAD Violet Viability Dye (Invitrogen, Carlsbad, CA, USA) were added, and the cells were stained with antibodies to CD14 Pacific Blue, CD20 Pacific Blue (Exbio Praha) and CD8 Pacific Orange (Invitrogen) for 15 min in the dark. Cells were then washed with a washing buffer (PBS containing 0.1% sodium azide and 2% gelatin from cold fish (Sigma-Aldrich)) and fixed using FACS lysing solution/FACS Perm 2 (BD Biosciences) according to the manufacturer's instructions. Following fixation and permeabilization, cells were washed and stained with CD3 PerCP-Cy5.5 (eBioscience, San Diego, CA, USA), CD4 ECD (Immunotech, Marseille, France) and with the intracellular markers IFNg PE Cy7, IL2 APC (eBioscience) and CD154 PE (Immunotech). Cells were then washed again.
Peptides and whole-CMV lysate A mixture of pools of 15 amino-acid peptides (11 overlaps) spanning the CMV IE-1 and pp65 proteins (JPT Peptides, Berlin, Germany) and whole-CMV lysate (Vidia, Prague, Czech Republic) were used for simultaneous CD4 þ and CD8 þ CMV-specific T-cells stimulation. Initial pilot study on seven post-HSCT patients and three healthy CMVseropositive donors showed that CD8 þ T-cell response was higher to pp65 in six individuals, to IE-1 in one individual and three individuals had the same response to both peptide mixes. CD4 þ T-cell response was the highest to the CMV lysate in five individuals. CD8 þ T-cell b Two patients were transplanted before year 2000 and they were monitored by CMV antigenemia only. They were repeatedly treated using ganciclovir during early post-HSCT period. c copies 410 but o100/10000 g.e. 
Statistical analysis
Contingency of patients' characteristics in Table 1 was evaluated by logistic regression. All intracellular cytokine staining data were backgroundsubtracted using CD28/49d co-stimulation only and results from pp65/IE-1/CMV lysate stimulation of CMV-seronegative volunteers. A lower threshold corresponding to one s.d. above the responses reached in specific stimulated wells of healthy CMV-seronegative volunteers were built, and values below these thresholds were set to zero. 26 Statistical significance of between-group comparisons was determined by Mann-Whitney U-test. A total of 15 primary T-cell response signatures with between-group comparisons were made, and so the level of statistical significance for these T-cell functional response signature in patients with CMV L Król et al comparisons was adjusted using a Bonferroni correction to Po0.003 (PX0.003 and o0.01 were considered to indicate borderline significance). GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA) was used for Mann-Whitney U-test calculations. This standard approach; however, does not take into the account the bias caused by unbalanced repeated measures design of our experiment. Therefore, mixed-effects model (R-project package 'lme4 r-cran', available at http://www. r-project.org) was used to validate the significance. The P-values were estimated by Markov chain Monte-Carlo simulation (referred to as p(MCMC) in the results: R-project package 'languageR').
Hierarchical clustering analysis was performed in the 'Stats' package of the R-project.
Results
Patients' characteristics
Patients' characteristics are summarized in Table 1 . All clinical and demographical variables were tested for the effect on the ability to control the CMV reactivations. Donor serostatus was the only variable with significant effect on CMV reactivation control. Surprisingly, neither the effect of acute GVHD nor chronic GVHD was found to be significant.
Relationship between signature profiles
It has been proposed that the quality of the T-cell response (different from merely the magnitude of the response) and the combinations of the optimal subtypes of T-cells are the relevant parameters for controlling any given pathogen. 24 To get a better insight into the relationships between the functional profiles, we subjected all seropositive individuals (post-transplant patients and healthy donors) to unsupervised hierarchical clustering commonly used in analyses of expression profiling data. When functional profiles were clustered according to the Pearson's correlation metrics, we found that the profiles branch to CD4 þ responses and CD8 þ responses. The CD8 þ responses further subdivided into three clusters (Figure 2) , whereas the CD4 þ responses offered only one distinct cluster. Of note, polyfunctional CD8 þ responses clustered together in 'CD8 helper' and 'CD8 master' cluster, whereas responses of single IFNg þ with/without degranulation ('CD8 firstline') were rather distant from the previous two clusters. Figure 1 Continued.
T-cell functional response signature in patients with CMV L Król et al
This analysis complements the analysis of profiles present in CMV-CR and CMV-NC patients (below) shown in Figure 3 and Supplementary Figures 1 and 2 , which show representations of signature magnitudes but do not allow to see relationship between the signatures on the individual patient/sample level. The signature profiles that cluster together are likely regulated by similar mechanisms (or driven by the same situation, such as Ag load, duration of response so on.). Thus we use the nicknames for each cluster throughout the paper.
Signatures profiles of CMV-specific T-cells in post-HSCT patients with CMV control
Functional signatures of CMV-specific T-cells in healthy CMV-seropositive donors with well-controlled chronic CMV infection have been established. 27 However, post-HSCT patients have much higher CMV viral loads and suffer from frequent CMV reactivation because of severe lymphopenia caused by the pre-transplant conditioning. 28 We have compared functional signatures in CMV-NAH, CMV-CR, CMV-NC and CMV-WR groups. As reference samples of controlled chronic infection and seronegativity without transplantation, we included healthy seropositive and seronegative donors. Among CD8 þ T-cells, we found three functional signatures (single IFNg þ , dual IFNg þ / IL2 þ and triple IFNg þ /IL2 þ /CD154 þ ) that significantly differed between CMV-CR and CMV-NC by nonparametric comparison (Figure 3) . When mixed-effect model was taken into account, only dual IFNg þ /IL2 þ 'CD8 master' signature was confirmed to be of borderline significance (p(MCMC)o0.01). Although single IFNg þ CD8 þ T-cells were the most frequent CMV-specific T-cells, they were not restricted to CMV controllers. A total of 14 out of 40 CMV-NC samples had detectable single IFNg þ CD8 þ T-cells (median 3.6%, range 0.06% to 15.7%) (Figure 3) . Thus, these cells are likely Ag-loaddependent 'first-line' responders that may be essential for a successful response, but are not sufficient when not supported by other functional subsets. In contrast, dual IFNg þ /IL2 þ 'CD8 master' T-cells were present in the majority of CMV-CR but were virtually absent in CMV-NC ( Figure 3) . We consider the dual IFNg þ /IL2 þ CD8 þ T-cells to be the 'CD8 master' CMV-controlling subset based on their high frequency, their presence in the majority of CMV-CR and their absence in CMV-NC. Triple IFNg þ /IL2 þ /CD154 þ positive CD8 þ T-cells represented a rare subset of a putative novel CD8 þ helper phenotype. No CD4 þ T-cell functional signatures differed between CMV-CR and CMV-NC. To test whether time post transplant was a relevant factor to be included into the analysis, we divided the data into three groups (0-6 months post-BMT, 46-12 months post-BMT, 412 month post-BMT) and analyzed by Kruskal-Wallis for differences between time groups (no differences found: Supplementary Figure 3. ) We also analyzed the data set by mixed-effects model with the time groups included as an additional factor. The only significant factor describing the difference between the CMV-CR and CMV-NC was again dual IFNg þ /IL2 þ signature (p(MCMCo0.01)).
A killer phenotype was found in patients with recent Ag encounter Patients with PCR-documented reactivations after transplantation (CMV-CR and CMV-NC groups) presented with T-cells with CMV-specific degranulation (CD8 þ : (Figure 3 , Supplementary Figure 1 and 2). These CD107a positive cells were more frequent in patients with reactivations than in seronegative patients, whereas we detected only few in seropositive donors without a significantly different frequency compared with seronegative donors. Thus, we conclude that this direct cytotoxicity-related phenotype 21, 22 is present mostly under conditions of recent high Ag load.
A putative helper phenotype was also found in CD8 þ T-cells Surprisingly, two functional 'CD8 helper' subsets of CD8 þ T-cells were detected with CD154 upregulation upon stimulation ( Figure 3 and Supplementary Figure 1) . The triple IFNg þ /IL2 þ /CD154 þ 'CD8 helper' CD8 þ T-cell subset was more frequent in CMV-CR than in CMV-NC group, whereas the IFNg þ /CD154 þ subset was on the edge of the sensitivity of our detection. In contrast to the killer phenotype, the triple positive 'CD8 helper' phenotype cells were detectable in 14 out of 27 (52%) of healthy seropositive donors (with presumably low viral load). We conclude that CD8 þ T-cells with 'CD8 helper' phenotype are long-lived memory T-cells.
CD4 þ helper T-cells
The most frequent CD4 þ specific response was found within the 'CD4 helper' cluster of cell subset upregulating IFNg and CD154 (Supplementary Figure 2) . This dual production was accompanied by production of IL2 in the second-most-frequent CD4 þ subset (falling also into 'CD4 helper' cluster). Although we found these cells more frequently in seropositive healthy individuals than in seronegative individuals, they were also more frequent in both CMV-CR and CMV-NC group, without a significant difference between the two. They were detectable in only 33% patients of the CMV-WR and were very rare, but detectable in more than 50% of healthy donors. Thus, we propose that they are also a long-lived memory subset of helper responders. The third 'CD4 helper' cluster profile (IL2 þ /CD154 þ ) was found in both, CMV-NC and CMV-CR, compared with seronegative or seropositive healthy donors regardless of the patients' ability to control CMV reactivation. A common functional feature of the 'CD4 helper' cluster profiles was CD154 positivity without degranulation. We detected a very rare dual IFNg þ /IL2 þ subset, but functional interpretation was difficult due to the paucity of these cells. Monofunctional IFNg þ , IL2 þ or CD107 þ subsets were also rather low, with the latter two found exclusively in CMV-NC. Surprisingly, the most polyfunctional CD4 þ subsets (quadruple positive and IFNg þ /CD107a þ /CD154 þ ) were not only rare but also only detectable in some post-HSCT patients with reactivations (CMV-CR and CMV-NC), and missing from healthy individuals.
Discussion
We have described functional signatures of CD4 þ and CD8 þ CMV-specific T-cells in clinically relevant groups of patients that are either controlling or not controlling CMV reactivation after HSCT. The number of individuals enrolled and the breadth of response followed in both the CD4 þ and CD8 þ T-cell subsets allowed us to obtain a unique set of clinically relevant correlates of immune control of CMV reactivations. Assessment of multiple functions on a per-cell basis allowed us to gain insight into the quality of the antiviral response, which is highly relevant in determining the outcome of the reactivation. 24, 29 The signature of the patients that controlled their CMV reactivation was a polyfunctional response of 'master' CD8 þ T-cells that produce IFNg and IL2 at the same time. Serostatus of donor and recipient impacted on the (Table 1) showed no impact on the control of CMV. Thus, we confirmed and extended the findings of Lilleri et al., 30 who reported a relationship between the dual IFNg/IL2 producing T-cells and protection from CMV reactivation in a smaller group of patients. These dual/polyfunctional cells were previously described as potent infection-controlling cells 31 that are more frequent in HIV long-time non-progressors 32 and missing in HIV progressors. 33 Loss of dual IFNg/IL2 production and persistence of single IFNg production were observed in exhausted LCMV-specific T-cells under high viral load in mice, 34 wherein IL2 was highly sensitive to negative regulation during chronic infection. The importance of dual IFNg/IL2 production was confirmed in HIV þ longtime non-progressors, where IFNg/IL2 dual-producing CD8 þ T-cells were found mostly in the central memory compartment and could proliferate in response to IL2 independently of CD4 þ T-cells. 32 The fact that the proliferation capacity of CMV-specific T-cells is associated with protection against CMV viremia or disease was reported previously. 16 Thus, IFNg single production may be a sign of functional exhaustion of virus-specific T-cells during chronic viral infection, as has been reported in several other studies. 2, [35] [36] [37] In light of our data, many studies that have focused on measuring single cytokines and chose IFNg would not have been able to differentiate an inefficient single IFNg response from an efficient master response. 14, 15, 38 A similar limitation applies to a report by Bunde et al., 39 who reported no correlation between pp65-stimulated CD8 þ T-cells and protection, whereas IE-1 stimulated CD8 þ Tcells correlated with protection. We included both pp65 and IE-1 peptide pools in our stimulation cocktail to show a broad response to CMV Ags. We speculate that the missing correlation to protection was at least in part due to the single IFNg producing cells monitored in the study by Bunde, where the 'master' dual IFNg/IL2 cells were missed.
The puzzling observation of putative CD8 þ helper Tcells (expressing CD40L) that were relevant for control of the CMV reactivations fits with data on CD8 þ helper Tcells in mice (A Thiel, M Frentsch, personal communication), and some earlier reports on a role of CD8 þ T-cells in providing an activation signal for DCs. 40 We also report on a rare subset of CMV-specific CD4 þ degranulating T-cells that are detectable in patients with a high Ag load. These cells were found to be MHC class IIrestricted cytotoxic T-cells. 41, 42 Cassaza 22 reported their ability to kill CMV Ag-loaded B-LCLs.
Monofunctional T-cells were inefficient, in concordance with previous studies. 43, 44 This may be related to the fact that polyfunctional T-cells produce higher levels of cytokines per cell, 45 but we suggest that the picture is more complex. To review the relationship between the functional subsets, we employed hierarchical clustering of the functional subtypes across seropositive individuals. Not surprisingly, the magnitude of 'CD8 first-line' single IFNg response cells (abundant in individuals with high viral load, possibly terminally differentiated or exhausted) is not closely related to other functional subset. Other polyfunctional CD8 þ responses divide into either 'CD8 helper' or 'CD8 master' cluster . Thus, we propose that to be clinically relevant, immune monitoring should include an evaluation of the concerted actions of different subsets rather than focusing on one type of response signature only.
Evaluating the influence of Ag load on the response signature is difficult in human studies. Nonetheless, a comparison of patients with a recent high viral load and undetectable CMV in the blood of healthy donors with a presumed low Ag load during controlled chronic infection allowed us to differentiate the signatures of recentlyactivated and long-lived memory T-cells.
The goal of clinical CMV-specific immune monitoring post-HSCT is to assist in clinical decision-making and, in particular, to decide whether or not to defer pre-emptive treatment in successfully reconstituted patients. This was carried out in a small-scale study by Avetisyan, where preemptive treatment was deferred when CMV-specific CD4 þ and CD8 þ T-cells producing IFNg were detected in patients with reactivation, as judged by an experienced hematologist. 46 Ideally, we would like to set up firm and reproducible criteria that could be built into treatment protocols. The presented study highlights multiple factors that need to be evaluated together to predict protection from CMV reactivation.
